Please enable JS

ARTICLES & TESTIMONIALS

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Dec 26/50SN Staff/ PCSK9i

A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association. Read more.

READ MORE

NEJM Study of Evolocumab Efficacy in Lowering LDL Cholesterol

Dec 26/50SN Staff/ PCSK9i

A study published in the New England Journal of Medicine found that Repatha® (evolocumab) reduced LDL cholesterol levels by 61 percent from pretreatment levels, and this reduction was sustained through 48 weeks. Patients taking evolocumab also showed a reduction in the rate of cardiovascular events. Learn more about the differences among LDL, HDL and triglycerides […]

READ MORE

Study Shows Safety and Efficacy of Anti-PCSK9 Antibodies in Lowering LDL Cholesterol

Dec 26/50SN Staff/ PCSK9i

A study published in BMC Medicine found that the anti-PCSK9 antibodies Repatha® (evolocumab) and Praluent® (alirocumab) reduced the LDL (bad) cholesterol level by over 50 percent, increased the HDL (good) cholesterol level, and resulted in favorable changes in other lipids. As some patients cannot tolerate statins, there is a need for alternative treatments that lower […]

READ MORE

Study Examines Impact of Cost Sharing on Specialty Drug Use

Dec 21/50SN Staff/ Specialty Tier Drugs

A study in the American Journal of Managed Care found that reductions in the use of specialty drugs in rheumatoid arthritis, cancer and multiple sclerosis are generally associated with higher cost sharing, though the effects vary by disease type. Read more

READ MORE

IFPA Reveals Findings of Non-Medical Switching Analysis

Dec 21/50SN Staff/ Non-Medical Switching

The Institute for Patient Access (IFPA) review of Medicare data for patients with rheumatoid arthritis (RA), Crohn’s disease or immunodeficiency found that concerns about the negative consequences of non-medical switching are warranted. Specifically, they concluded that non-medical switching can negatively impact patient care and increase healthcare expenses, particularly for RA patients. Read more.

READ MORE